Receiving a diagnosis of Chronic Myeloid Leukemia (CML) can be frightening, but it is important to understand that the management of this disease is one of the greatest success stories in modern ...
The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, ...
Key abstracts on chronic myeloid leukemia (CML) treatment from the 2025 American Society of Hematology Annual Meeting and Exposition are reported by Dr Jorge Cortes from the Georgia Cancer Center in ...
Bosutinib approved for chronic myelogenous leukemia The FDA has approved bosutinib (Bosulif, Pfizer) for patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML, who are ...
It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...
Suboptimal response or treatment failure to standard-dose imatinib are relevant problems in chronic-phase chronic myeloid leukemia patients. Insufficient adherence is one of the main causes of ...
Results from the phase 3 ENDURE trial (NCT03117816), newly published in Leukemia, demonstrate that ropeginterferon alfa-2b ...
The MarketWatch News Department was not involved in the creation of this content. -- Scemblix(R) is first to show superior efficacy and a favourable safety and tolerability profile in a Phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback